2Jackman DM, Yeap BY, Lindeman NI, et al. Phase Ⅱ clinical trial of chemotherapy-naive patients > or = 70 years of age treated with erlotinib for untreated advanced non-small cell cancer(NSCLS) :an analysis of life and symptom response[J]. J Clin Oncol,2007,25(7) :760-766.
3Sridhar SS, Seymou L, Shepherd FA. Inhibitors of epidermalgrowth-factor receptors a review of clinical research with a focus on non-small cell lung cancer[J]. Lancet Oncol,2003,4(7) :397- 406.
1Yarden Y.The EGFR family and its lig ands in human cancer.signalling mechanisms and therapeutic opportunities.Eur J Cancer,2001,37 Suppl 4:S3-S8.
2Aaronson SA.Growth factors and cancer.Science,1991,254(5035):1146-1153.
3Earp HS 3rd,Calvo BF,Sartor CI.The EGF receptor family-multiple roles in proliferation,differentiation,and neoplasia with an emphasis on HER4.Trans Am Clin Climatol Assoc,2003,114:315-334.
4Mendelsohn J.The EGF receptor as a target for cancer therapy.Endocrine Related Cancer,2001,8:3-9.
5Nicholson RI,Gee JM,Harper ME.EGFR and cancer prognosis.Eur J Cancer,2001,37 Suppl 4:S9-S15.
6Herbst RS.Targeted therapy in non-small-cell lung cancer.Orcology (Huntingt),2002,16(9 Suppl 9):19-24.
7Mendelsohn J,Baselga J.Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.J Clin Oncol,2003,21(14):2787-2799.
8Fuster LM,Sandler AB.Select clinical trials of erlotinib (OSI-774) in non-small-cell lung cancer with emphasis on phase Ⅲ outcomes.Clin Lung Cancer,2004,6 Suppl 1:S24-S29.
9Kanematsu T,Yano S,Uehara H,et al.Phosphorylation,but not overexpression,of epidermal growth factor receptor is associated with poor prognosis of non-small cell lung cancer patients.Oncol Res,2003,13(5):289-298.
10Moyer JD,Barbacci EG,Iwata KK,et al.Induction of apoptosis and cell cycle arrest by CP-358,774,an inhibitor of epidermal growth factor receptor tyrosine kinase.Cancer Res,1997,57(21):4838-4848.
1Shepherd FA, Rodrigues Pereira J, Ciuleanu T, et al. Erlotinib in pre- viously treated non-small-cell lung cancer [ J ]. N Engl J Med, 2005, 353(2) :123.
2Bezjak A, Tu D, Seymour L, et al. Symptom improvement in lung cancer patients treated with erlotinib: quality of life analysis of the National Cancer Institute of Canada Clinical Trials Group Study BR21 [J]. J Clin Oncol,2006,24(24) :3831.
3Pao W, Miller VA, Politi KA, et al. Acquired resistance of lung adeno- carcinomas to gefitinib or erlotinib is associated with a second muta- tion in the EGFR kinase domain[ J]. PLoS Med,2005,2 (3) :225.
4Engelman JA, Zejnullahu K, Mitsudomi T, et al. MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 sig- naling[ J ]. Science ,2007,316 ( 5827 ) : 1039.
5Herbst RS,Johnson DH,Mininberg E,et al. Phase trial evalua-ting the anti-vascular endothelial growth factor monoclonal antibody bevacizumab in combination with the HER-I/epidermal growth factor receptor tyrosine kinase inhibitor erlotinib for patients with recurrent non-small-cell lung cancer[ J ]. J Clini Onco1,2005,23 ( 11 ) :2544.
6Uramoto H, Iwata T, Onitsuka T, et al. Epithelial -mesenchymal tran- sition in E GFR-TKI acquired resistant lung adenocarcinoma[ J ]. Anti- cancer Res,2010,30(7) :2513.
7Lee JS, Hirsh V, Park K, et al. Vandetanib versus placebo in patients with advanced non-small-cell lung cancer after prior therapy with an epidermal growth factor receptor tyrosine kinase inhibitor:A random- ized, double-blind phase Ill trial (ZEPHYR) [ J ]. J Clin Oncol,2012, 30(10) :1114.
8Yano S, Nakataki E, Ohtsuka S, et al. Retreatment of lung adenocarci- noma patients with gefitinib who had experienced favorable results from their initial treatment with this selective epidermal growth factor receptor inhibitor: a report of three eases [ J ]. Oncol Res, 2005,15 (2) :107.
9Schiller JH, Lee JW, Hanna NH, et al. A randomized discontinuation phase II study of sorafenib versus placebo in patients with non-small cell lung cancer who have failed at least two prior chemotherapy regi- mens : E2501 [ J ]. J Clin Onco1,2008,26 ( suppl 15 ) : 8014.
